CN1077885C - 联苯基磺酰胺基质金属蛋白酶抑制剂 - Google Patents

联苯基磺酰胺基质金属蛋白酶抑制剂 Download PDF

Info

Publication number
CN1077885C
CN1077885C CN97194719A CN97194719A CN1077885C CN 1077885 C CN1077885 C CN 1077885C CN 97194719 A CN97194719 A CN 97194719A CN 97194719 A CN97194719 A CN 97194719A CN 1077885 C CN1077885 C CN 1077885C
Authority
CN
China
Prior art keywords
compound
alkyl
sulfonylamino
acid
methylbutanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97194719A
Other languages
English (en)
Chinese (zh)
Other versions
CN1219166A (zh
Inventor
P·M·奥伯里恩
D·R·斯里斯科威克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1219166A publication Critical patent/CN1219166A/zh
Application granted granted Critical
Publication of CN1077885C publication Critical patent/CN1077885C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN97194719A 1996-05-17 1997-04-24 联苯基磺酰胺基质金属蛋白酶抑制剂 Expired - Fee Related CN1077885C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
US60/017,460 1996-05-17

Publications (2)

Publication Number Publication Date
CN1219166A CN1219166A (zh) 1999-06-09
CN1077885C true CN1077885C (zh) 2002-01-16

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97194719A Expired - Fee Related CN1077885C (zh) 1996-05-17 1997-04-24 联苯基磺酰胺基质金属蛋白酶抑制剂

Country Status (22)

Country Link
EP (1) EP0901466B1 (enExample)
JP (1) JP2000511175A (enExample)
KR (1) KR20000011095A (enExample)
CN (1) CN1077885C (enExample)
AT (1) ATE207891T1 (enExample)
BG (1) BG63940B1 (enExample)
BR (1) BR9710841A (enExample)
CA (1) CA2253342A1 (enExample)
CZ (1) CZ294063B6 (enExample)
DE (1) DE69707865T2 (enExample)
DK (1) DK0901466T3 (enExample)
EA (1) EA001561B1 (enExample)
EE (1) EE03965B1 (enExample)
ES (1) ES2167733T3 (enExample)
IL (1) IL126832A0 (enExample)
NO (1) NO312510B1 (enExample)
NZ (1) NZ332711A (enExample)
PL (1) PL186416B1 (enExample)
PT (1) PT901466E (enExample)
SK (1) SK282863B6 (enExample)
WO (1) WO1997044315A1 (enExample)
ZA (1) ZA974223B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2193691A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
KR20000057444A (ko) * 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 심기능부전 및 심실확장의 치료 및 예방 방법
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
ES2212142T3 (es) 1996-12-17 2004-07-16 Warner-Lambert Company Llc Uso de inhibidores de metaloproteinasas de la matriz para promover la curacion de heridas.
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
JP3621427B2 (ja) * 1997-07-22 2005-02-16 塩野義製薬株式会社 糸球体障害治療または予防剤
EP1047450B1 (en) * 1997-12-23 2002-10-02 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
JP4750272B2 (ja) * 1998-02-04 2011-08-17 ノバルティス アーゲー マトリックス分解メタロプロテイナーゼを阻害するスルホニルアミノ誘導体
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
EP1063991A1 (en) * 1998-03-17 2001-01-03 Warner-Lambert Company Llc Statin-matrix metalloproteinase inhibitor combinations
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
AU754050B2 (en) 1998-07-16 2002-10-31 Sanofi-Aventis Deutschland Gmbh Phosphinous and phosphonic acid derivatives used as medicaments
CN1310629A (zh) * 1998-07-21 2001-08-29 沃尼尔·朗伯公司 用于治疗动脉粥样硬化损伤的acat和mmp抑制剂的合并给药
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU765203B2 (en) * 1999-04-19 2003-09-11 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
SI1249233T1 (sl) 1999-11-26 2009-02-28 Shionogi & Co Antagonisti NPYY5
CA2423885A1 (en) * 2000-09-29 2003-03-27 Shionogi & Co., Ltd. Thiazole and oxazole derivatives
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
CA2548513A1 (en) * 2003-12-04 2005-07-07 Wyeth Biaryl sulfonamides and methods for using same
WO2005092844A1 (en) 2004-03-22 2005-10-06 Southern Research Institute Nonpeptide inhibitors of matrix metalloproteinases
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035276A1 (en) * 1994-06-22 1995-12-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035276A1 (en) * 1994-06-22 1995-12-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
CA2253342A1 (en) 1997-11-27
SK282863B6 (sk) 2002-12-03
IL126832A0 (en) 1999-08-17
ZA974223B (en) 1997-12-10
HK1019585A1 (en) 2000-02-18
PT901466E (pt) 2002-04-29
DK0901466T3 (da) 2002-02-18
KR20000011095A (ko) 2000-02-25
NO312510B1 (no) 2002-05-21
EA199800988A1 (ru) 1999-04-29
PL186416B1 (pl) 2004-01-30
EA001561B1 (ru) 2001-04-23
ATE207891T1 (de) 2001-11-15
CZ366898A3 (cs) 1999-02-17
SK157798A3 (en) 1999-04-13
DE69707865D1 (de) 2001-12-06
JP2000511175A (ja) 2000-08-29
EE9800397A (et) 1999-06-15
BG63940B1 (bg) 2003-07-31
PL329929A1 (en) 1999-04-26
NO985326L (no) 1999-01-14
EP0901466B1 (en) 2001-10-31
DE69707865T2 (de) 2002-05-02
BR9710841A (pt) 1999-08-17
NZ332711A (en) 2000-06-23
ES2167733T3 (es) 2002-05-16
EE03965B1 (et) 2003-02-17
CN1219166A (zh) 1999-06-09
CZ294063B6 (cs) 2004-09-15
AU2680397A (en) 1997-12-09
BG102918A (en) 1999-09-30
EP0901466A1 (en) 1999-03-17
NO985326D0 (no) 1998-11-16
AU713286B2 (en) 1999-11-25
WO1997044315A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
CN1077885C (zh) 联苯基磺酰胺基质金属蛋白酶抑制剂
CN1213019C (zh) 磺酰胺和羧酰胺衍生物和含这种化合物作活性成分的药物
CN1280267C (zh) 磺酰氨基羧酸
CN1196671C (zh) 单和双取代的3－丙基－γ－氨基丁酸
CN1279673A (zh) (环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CN1230177A (zh) 作为基质金属蛋白酶抑制剂的β－磺酰基异羟肟酸
CN1551866A (zh) 羧酸衍生物化合物及包含这些化合物为活性成分的药物
CN1198096A (zh) 用于治疗与胶原蛋白过量产生有关的疾病的c－蛋白酶抑制剂
CN1278247A (zh) 作为基质金属蛋白酶抑制剂的β－磺酰基异羟肟酸的α－羟基、－氨基和卤代衍生物
CN1140508C (zh) 作为基质金属蛋白酶抑制剂的取代4-联苯基-4-羟基丁酸衍生物
CN1366518A (zh) 作为基质金属蛋白酶抑制剂的联苯基丁酸衍生物
CN1090282A (zh) 苯稠合羟基取代的环烷基和杂环化合物的磺酰胺衍生物
CN1835743A (zh) 用于治疗代谢紊乱的化合物
CN1033800A (zh) 茚满衍生物和其制备方法
CN1051354A (zh) 取代环烷并[b]二氢吲哚-和-吲哚磺酰胺
CN1419549A (zh) 不对称的4,6－双(芳氧基)嘧啶衍生物的制备方法
CN1212835C (zh) 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂
CN1125815C (zh) 用于合成喹啉衍生物的方法
CN1087295C (zh) 环氧琥珀酸衍生物
CN1705648A (zh) 具有ACAT抑制活性的а－苯基N－乙酰苯胺衍生物及其治疗应用
CN1125045C (zh) 2－亚氨基噻唑啉衍生物的制备方法中的中间产物的制备方法
CN1097745A (zh) 取代的哌嗪
CN87107427A (zh) 取代的氨甲基-5，6，7，8-四氢萘氧代乙酸，新的中间体产物，它们的制备过程及其作为药物的应用
CN1163472C (zh) 用于制备手性氨基酸的新方法
CN1062525A (zh) 苯基烷氨基化合物及其制造方法以及含这些化合物的药剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee